Saracatinib difumarate
Based on 42 publication(s) in Google Scholar
Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 893428-72-3
- Formula: C35H40ClN5O13
- Molecular Weight:774.17
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Saracatinib difumarate
More- Signal Transduct Target Ther. 2023 Feb 17;8(1):66. [Abstract]
- Cancer Res. 2024 Feb 1;84(3):479-492. [Abstract]
- Nat Commun. 2025 Apr 7;16(1):3319. [Abstract]
- Nat Commun. 2023 Apr 24;14(1):2342. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Neuro Oncol. 2026 Jan 7:noaf297. [Abstract]
- Leukemia. 2012 Oct;26(10):2233-44. [Abstract]
- EBioMedicine. 2022 Dec:86:104374. [Abstract]
- Int J Biol Sci. 2025 Mar 31;21(6):2780-2805. [Abstract]
- Cell Death Dis. 2025 Feb 3;16(1):64. [Abstract]
- Cell Death Dis. 2021 Dec 3;12(12):1126. [Abstract]
- Cell Death Dis. 2020 Aug 7;11(8):652. [Abstract]
- Acta Neuropathol. 2025 May 14;149(1):48. [Abstract]
- Int J Biol Macromol. 2026 May 27:152746. [Abstract]
- Int J Biol Macromol. 2026 Jan:336:149150. [Abstract]
- Phytomedicine. 2025 Oct 8:148:157387. [Abstract]
- J Orthop Translat. 2022 Feb 16:33:55-69. [Abstract]
- Biomed Pharmacother. 2021 Dec 6;146:112487. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696. [Abstract]
- Cell Rep. 2022 Mar 8;38(10):110462. [Abstract]
- Cancer Cell Int. 2021 Dec 7;21(1):655. [Abstract]
- Biochem Pharmacol. 2026 Aug;250(Pt 2):118028. [Abstract]
- Biochem Pharmacol. 2026 Jun 25;251(Pt 2):118189. [Abstract]
- Biochem Pharmacol. 2025 Jun 2:239:117014. [Abstract]
- Cell Prolif. 2023 Jan;56(1):e13337. [Abstract]
- Mol Cancer Ther. 2017 Nov;16(11):2387-2398. [Abstract]
- Int J Mol Sci. 2021 Aug 27;22(17):9289. [Abstract]
- Cancer Sci. 2018 Jun;109(6):1949-1957. [Abstract]
- J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]
- iScience. 2022 Sep 19;25(10):105171. [Abstract]
- Oncol Rep. 2018 Aug;40(2):635-646. [Abstract]
- J Virol. 2026 Apr 21;100(4):e0024126. [Abstract]
- Cell Signal. 2025 Mar 29:111781. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Arch Biochem Biophys. 2018 May 1:645:54-60. [Abstract]
- Preprints. 2025 Sep 22.
- bioRxiv. 2024 Nov 6:2024.11.04.621884. [Abstract]
- bioRxiv. 2024 July 09.
- bioRxiv. 2023 Dec 14.
- Research Square Preprint. 2021 Jul.
- Technical University of Munich. 24.01.2018.
- Oncotarget. 2015 Sep 29;6(29):27160-75. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
WB
Biological Activity
IC50: 2.7 nM (Src), 30 nM (v-Abl), 66 nM (EGFR), 200 nM (c-Kit)[1]
Chemical Information
-
CAS No. 893428-72-3
-
Appearance Solid
-
Molecular Weight 774.17
-
Formula C35H40ClN5O13
-
Color Off-white to light yellow
-
SMILES
ClC1=CC=C2C(OCO2)=C1NC3=C4C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=CC4=NC=N3.OC(/C=C/C(O)=O)=O.OC(/C=C/C(O)=O)=O
-
Synonyms
AZD0530 difumarate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (42)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with β-catenin. [Abstract]2023 Feb 17;8(1):66. PMID: 36797256
Saracatinib difumarate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Feb 17;8(1):66. [Abstract]
Saracatinib (10 μM) reduces BLK-mediated FAM83A tyrosine phosphorylation in HEK293T cells.
-
Cancer Res
Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. [Abstract]2024 Feb 1;84(3):479-492. PMID: 38095536 -
Nat Commun
p38 mediated ACSL4 phosphorylation drives stress-induced esophageal squamous cell carcinoma growth through Src myristoylation. [Abstract]2025 Apr 7;16(1):3319. PMID: 40195298 -
Nat Commun
TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. [Abstract]2023 Apr 24;14(1):2342. PMID: 37095176 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Neuro Oncol
MBD3 deficiency decommissions the NuRD complex and orchestrates the epigenetic regulation of gene expression to suppress neuroblastoma progression. [Abstract]2026 Jan 7:noaf297. PMID: 41499431 -
Leukemia
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. [Abstract]2012 Oct;26(10):2233-44. PMID: 22469781 -
EBioMedicine
Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model. [Abstract]2022 Dec:86:104374. PMID: 36455410 -
Int J Biol Sci
Macrophage KDM2A promotes atherosclerosis via regulating FYN and inducing inflammatory response. [Abstract]2025 Mar 31;21(6):2780-2805. PMID: 40303308 -
Cell Death Dis
Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway. [Abstract]2025 Feb 3;16(1):64. PMID: 39900894 -
Cell Death Dis
Hippo signaling suppresses tumor cell metastasis via a Yki-Src42A positive feedback loop. [Abstract]2021 Dec 3;12(12):1126. PMID: 34862372 -
Cell Death Dis
FYN is required for ARHGEF16 to promote proliferation and migration in colon cancer cells. [Abstract]2020 Aug 7;11(8):652. PMID: 32811808 -
Acta Neuropathol
2025 May 14;149(1):48. PMID: 40366450 -
Int J Biol Macromol
SLC39A1 promotes pancreatic cancer metastasis by elevating intracellular zinc and activating the Src/FAK signaling pathway. [Abstract]2026 May 27:152746. PMID: 42208832 -
Int J Biol Macromol
Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma. [Abstract]2026 Jan:336:149150. PMID: 41274476 -
Phytomedicine
Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer. [Abstract]2025 Oct 8:148:157387. PMID: 41106095 -
J Orthop Translat
Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway. [Abstract]2022 Feb 16:33:55-69. PMID: 35228997 -
Biomed Pharmacother
Periplocin ameliorates mouse age-related meibomian gland dysfunction through up-regulation of Na/K-ATPase via SRC pathway. [Abstract]2021 Dec 6;146:112487. PMID: 34883449 -
Cell Mol Gastroenterol Hepatol
2021;11(3):683-696. PMID: 33075564 -
Cell Rep
Nociceptor-derived Reg3γ prevents endotoxic death by targeting kynurenine pathway in microglia. [Abstract]2022 Mar 8;38(10):110462. PMID: 35263589 -
Cancer Cell Int
Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation. [Abstract]2021 Dec 7;21(1):655. PMID: 34876150 -
Biochem Pharmacol
Divergent mechanisms, unified therapy: saracatinib targets Src/HIF signaling in endothelial and microglial cells to treat retinopathy. [Abstract]2026 Aug;250(Pt 2):118028. PMID: 42070593 -
Biochem Pharmacol
2026 Jun 25;251(Pt 2):118189. PMID: 42349620 -
Biochem Pharmacol
IFITM1 promotes proliferation, migration and macrophage-like transdifferentiation of vascular smooth muscle cells via c-Src/MAPK/GATA2/E2F2 pathway in atherosclerosis. [Abstract]2025 Jun 2:239:117014. PMID: 40466954 -
Cell Prolif
PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness. [Abstract]2023 Jan;56(1):e13337. PMID: 36127291 -
Mol Cancer Ther
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. [Abstract]2017 Nov;16(11):2387-2398. PMID: 28775147 -
Int J Mol Sci
2021 Aug 27;22(17):9289. PMID: 34502195 -
Cancer Sci
2018 Jun;109(6):1949-1957. PMID: 29601121 -
J Cell Mol Med
Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion. [Abstract]2019 Apr;23(4):2399-2409. PMID: 30677226
Saracatinib difumarate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]
Immunoblot analysis of p-JNK1/2 (T183/Y185) in HepG2 cells treated with saracatinib (10 μM, 12 h) and PP1 (10 μM, 2 h).
-
iScience
Inhibition of SRC-mediated integrin signaling in bone marrow niche enhances hematopoietic stem cell function. [Abstract]2022 Sep 19;25(10):105171. PMID: 36204266 -
Oncol Rep
Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. [Abstract]2018 Aug;40(2):635-646. PMID: 29917168 -
J Virol
2026 Apr 21;100(4):e0024126. PMID: 41914886 -
Cell Signal
Annexin A2 binds the 3'-UTR of H2AX mRNA and regulates histone-H2AX-derived hypoxia-inducible factor 1-alpha activation. [Abstract]2025 Mar 29:111781. PMID: 40164417 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Arch Biochem Biophys
miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. [Abstract]2018 May 1:645:54-60. PMID: 29550144
Saracatinib difumarate purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2018 May 1:645:54-60. [Abstract]
SK-BR-3, MCF-7, and MDA-MB-231 cells are treated with 1 μM Saracatinib for 48 h. After treatment, the Src protein expression is determined by western blot.
-
-
bioRxiv
PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]2024 Nov 6:2024.11.04.621884. PMID: 39574568 -
-
-
-
-
Oncotarget
2015 Sep 29;6(29):27160-75. PMID: 26320174
Solvent & Solubility
DMSO : 83.33 mg/mL (107.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2917 mL | 6.4585 mL | 12.9171 mL | 32.2926 mL |
| 5 mM | 0.2583 mL | 1.2917 mL | 2.5834 mL | 6.4585 mL | |
| 10 mM | 0.1292 mL | 0.6459 mL | 1.2917 mL | 3.2293 mL | |
| 15 mM | 0.0861 mL | 0.4306 mL | 0.8611 mL | 2.1528 mL | |
| 20 mM | 0.0646 mL | 0.3229 mL | 0.6459 mL | 1.6146 mL | |
| 25 mM | 0.0517 mL | 0.2583 mL | 0.5167 mL | 1.2917 mL | |
| 30 mM | 0.0431 mL | 0.2153 mL | 0.4306 mL | 1.0764 mL | |
| 40 mM | 0.0323 mL | 0.1615 mL | 0.3229 mL | 0.8073 mL | |
| 50 mM | 0.0258 mL | 0.1292 mL | 0.2583 mL | 0.6459 mL | |
| 60 mM | 0.0215 mL | 0.1076 mL | 0.2153 mL | 0.5382 mL | |
| 80 mM | 0.0161 mL | 0.0807 mL | 0.1615 mL | 0.4037 mL | |
| 100 mM | 0.0129 mL | 0.0646 mL | 0.1292 mL | 0.3229 mL |
Saracatinib difumarate Related Classifications
HY-10234A Related Classifications
Powered by Bioz